What is the price of Moderna (MRNA) today?

The price of Moderna (MRNA) today is $ 49.20, with return of 77.49% compared to the last year. The price of Moderna (MRNA) started the year trading around $ 29.49 and today it is at $ 49.20. Follow the real-time price chart, the historical price of Moderna (MRNA) and international markets.

When does Moderna (MRNA) pay dividends?

Moderna (MRNA) did not distribute dividends in the last year.

Is Moderna (MRNA) worth it?

Currently, Moderna (MRNA) is priced at $ 49.20, with a P/E of -7.06%, representing a deviation of -277% from its historical average P/E. In the last year, the stock showed a variation of 77.49 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 77.49%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy Moderna (MRNA) stock?

Investing in stocks of Moderna (MRNA) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of Moderna (MRNA) yield today?

The yield of Moderna (MRNA) was -1.26% in the last month, 77.49% in the last year and -62.88% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.If you wanted to buy 100 stocks of Moderna (MRNA) today, the total investment would be $ 4,920.00, based on the current price of $ 49.20.If past performance were to repeat, the return on your investment would be:In 1 year: $ 8,732.51In 5 years: $ 1,826.30In 10 years: $ 4,920.00It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Moderna (MRNA): Stock Price, Earnings & Key Metrics

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	21.61	7.31	33.81%	2.16%	$ 579.24 B	28.46%
PFE	19.79	1.65	8.35%	6.36%	$ 153.75 B	12.42%
ABBV	87.56	0.00	0.00%	3.18%	$ 370.01 B	6.91%
NVO	10.22	5.26	51.50%	4.68%	$ 160.05 B	33.05%
MRK	16.27	0.00	0.00%	2.74%	$ 296.92 B	28.08%
AZN	28.58	6.00	20.99%	1.70%	$ 292.24 B	17.41%
GILD	19.48	7.33	37.62%	2.39%	$ 165.80 B	28.90%
BMY	16.90	-3.50	-20.72%	4.25%	$ 119.19 B	14.64%
ZTS	18.57	14.90	80.25%	1.79%	$ 49.65 B	28.23%
REGN	16.87	2.43	14.41%	0.49%	$ 75.98 B	31.41%
HALO	22.95	148.99	649.21%	0.00%	$ 7.27 B	22.69%
AMGN	24.38	21.71	89.06%	2.77%	$ 187.99 B	20.98%
MCK	24.38	-1,068.68	-4,383.84%	0.36%	$ 105.80 B	1.09%
VRTX	27.83	5.89	21.18%	0.00%	$ 110.00 B	32.94%
CAH	29.33	-18.06	-61.56%	0.99%	$ 48.75 B	0.68%
ADMA	14.98	4.61	30.78%	0.00%	$ 2.20 B	28.80%
BIIB	20.90	1.48	7.08%	0.00%	$ 27.02 B	13.07%
HRMY	9.53	1.74	18.24%	0.00%	$ 1.51 B	18.27%

Moderna, Inc. is a U.S.-based biotechnology company focused on the development of messenger RNA (mRNA)–based vaccines and therapeutics. Its platform enables the design of treatments that instruct cells to produce proteins capable of preventing or treating diseases.

The company’s model is centered on scalable, adaptable biotechnology, allowing rapid development across multiple therapeutic areas.

Core activities include:

Development of mRNA-based vaccines and therapeutics
Infectious disease and pandemic-response solutions
Oncology and personalized cancer therapies
Rare-disease and autoimmune treatments
Clinical research and biologics manufacturing

Moderna operates globally, with presence across the United States, Europe, and Asia, supported by partnerships with governments, research institutions, and healthcare organizations.

Its performance is influenced by regulatory approvals, clinical trial outcomes, R&D investment cycles, global vaccine demand, and advances in biotechnology platforms.

Moderna, Inc. is listed on the Nasdaq under the ticker MRNA.

History and Development

Moderna was founded in 2010 in Massachusetts by Derrick Rossi, Noubar Afeyan, Kenneth Chien, and Robert Langer, with the goal of advancing mRNA technology for therapeutic use.

Throughout the 2010s, the company expanded its research capabilities, built manufacturing infrastructure, and established strategic scientific partnerships.

In 2018, Moderna completed its initial public offering (IPO), marking one of the largest biotech listings at the time.

A major milestone came in 2020 with the development of its COVID-19 vaccine (mRNA-1273), which brought global recognition to mRNA technology.

Since then, the company has continued to expand its pipeline, focusing on new vaccines and therapeutic applications across multiple disease areas.

MRNA

Moderna Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment MRNA

review the fundamentals of Moderna shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Moderna

Moderna Inc.

United States

10 years

2018

1.300

History and Development

Additional Information

PROFIT X PRICE MRNA

Financial Results MRNA

MRNA cash flow

Asset, Revenue and Profit Growth - MRNA

MRNA balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca